Author:
Kumar S K,Flinn I,Noga S J,Hari P,Rifkin R,Callander N,Bhandari M,Wolf J L,Gasparetto C,Krishnan A,Grosman D,Glass J,Sahovic E A,Shi H,Webb I J,Richardson P G,Rajkumar S V
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference29 articles.
1. Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516–2520.
2. Brenner H, Gondos A, Pulte D . Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008; 111: 2521–2526.
3. Jagannath S, Durie BG, Wolf JL, Camacho ES, Irwin D, Lutzky J et al. Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma. Br J Haematol 2009; 146: 619–626.
4. Harousseau JL, Attal M, Leleu X, Troncy J, Pegourie B, Stoppa AM et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006; 91: 1498–1505.
5. Harousseau JL, Mathiot C, Attal M, Marit G, Caillot D, Hulin C et al. Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantation (ASCT) in previously untreated multiple myeloma (MM): updated data from IFM 2005/01 trial. J Clin Oncol 2008; 26: 455s . Abstract 8505; updated data presented at the ASH 2008 joint ASH/ASCO symposium.
Cited by
70 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献